FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156306288> ?p ?o ?g. }

• W2156306288 abstract "To assess the rate of objective response to pegylated liposomal doxorubicin hydrochloride (Caelyx) in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL).Prospective, open, multicenter study.Thirteen dermatology departments in France.Twenty-five patients with either (1) stage II to stage IV CTCL previously unsuccessfully treated with at least 2 lines of treatments or (2) histologically transformed epidermotropic CTCL requiring chemotherapy.Administration of Caelyx intravenously once every 4 weeks at a dose of 40 mg/m(2).The response to treatment was evaluated by clinical evaluation.At the end of treatment, we observed an objective response (primary end point) in 56% of the patients (14 of 25): 5 complete responses and 9 partial responses. The median overall survival time was 43.7 months. For the 14 patients who experienced an objective response, the median progression-free survival time after the end of treatment was 5 months.This prospective study demonstrates the effectiveness of Caelyx in treating CTCL, with an overall response rate of 56% in spite of the high proportion of patients with advanced-stage disease. Responses were observed in 2 subpopulations of patients in which the prognosis is known to be poorer: Sézary syndrome (overall response rate, 60%) and transformed CTCL (overall response rate, 50%). Moreover, this study shows that dose escalation to 40 mg/m(2) does not seem to improve the effectiveness but increases toxic effects (especially hematologic toxic effects) compared with the dose previously tested of 20 mg/m(2)." @default.
• W2156306288 created "2016-06-24" @default.
• W2156306288 creator A5001247907 @default.
• W2156306288 creator A5002644565 @default.
• W2156306288 creator A5005673493 @default.
• W2156306288 creator A5006277322 @default.
• W2156306288 creator A5014376121 @default.
• W2156306288 creator A5018464286 @default.
• W2156306288 creator A5035899929 @default.
• W2156306288 creator A5043326366 @default.
• W2156306288 creator A5048145652 @default.
• W2156306288 creator A5050985511 @default.
• W2156306288 creator A5053219695 @default.
• W2156306288 creator A5059416542 @default.
• W2156306288 creator A5059800915 @default.
• W2156306288 creator A5066869362 @default.
• W2156306288 creator A5081435878 @default.
• W2156306288 creator A5087445295 @default.
• W2156306288 creator A5089382487 @default.
• W2156306288 creator A5090133438 @default.
• W2156306288 date "2008-06-01" @default.
• W2156306288 modified "2023-10-17" @default.
• W2156306288 title "Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome" @default.
• W2156306288 cites W132679277 @default.
• W2156306288 cites W1582821616 @default.
• W2156306288 cites W1606079760 @default.
• W2156306288 cites W1749229087 @default.
• W2156306288 cites W176755457 @default.
• W2156306288 cites W1774588303 @default.
• W2156306288 cites W1914109980 @default.
• W2156306288 cites W1917060610 @default.
• W2156306288 cites W1970321630 @default.
• W2156306288 cites W1973857786 @default.
• W2156306288 cites W1988679162 @default.
• W2156306288 cites W1989716470 @default.
• W2156306288 cites W1991858554 @default.
• W2156306288 cites W1997916653 @default.
• W2156306288 cites W1999585694 @default.
• W2156306288 cites W2008594853 @default.
• W2156306288 cites W2020904611 @default.
• W2156306288 cites W2022765714 @default.
• W2156306288 cites W2023392634 @default.
• W2156306288 cites W2028950818 @default.
• W2156306288 cites W2029996357 @default.
• W2156306288 cites W2037904834 @default.
• W2156306288 cites W2040281943 @default.
• W2156306288 cites W2040390735 @default.
• W2156306288 cites W2040940474 @default.
• W2156306288 cites W2042019638 @default.
• W2156306288 cites W2045733649 @default.
• W2156306288 cites W2053681261 @default.
• W2156306288 cites W2059123617 @default.
• W2156306288 cites W2067747597 @default.
• W2156306288 cites W2072936571 @default.
• W2156306288 cites W2076668534 @default.
• W2156306288 cites W2086591674 @default.
• W2156306288 cites W2098397327 @default.
• W2156306288 cites W2113349793 @default.
• W2156306288 cites W2117903085 @default.
• W2156306288 cites W2135087888 @default.
• W2156306288 cites W2148845753 @default.
• W2156306288 cites W2153333333 @default.
• W2156306288 cites W2154603047 @default.
• W2156306288 cites W2161580101 @default.
• W2156306288 cites W2165526755 @default.
• W2156306288 cites W2167942239 @default.
• W2156306288 cites W2171085309 @default.
• W2156306288 cites W2244683952 @default.
• W2156306288 cites W2253754224 @default.
• W2156306288 cites W2397714772 @default.
• W2156306288 cites W2401977930 @default.
• W2156306288 cites W2408124722 @default.
• W2156306288 cites W2413754014 @default.
• W2156306288 cites W298819183 @default.
• W2156306288 cites W47357987 @default.
• W2156306288 doi "https://doi.org/10.1001/archderm.144.6.727" @default.
• W2156306288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18559761" @default.
• W2156306288 hasPublicationYear "2008" @default.
• W2156306288 type Work @default.
• W2156306288 sameAs 2156306288 @default.
• W2156306288 citedByCount "93" @default.
• W2156306288 countsByYear W21563062882012 @default.
• W2156306288 countsByYear W21563062882013 @default.
• W2156306288 countsByYear W21563062882014 @default.
• W2156306288 countsByYear W21563062882015 @default.
• W2156306288 countsByYear W21563062882016 @default.
• W2156306288 countsByYear W21563062882017 @default.
• W2156306288 countsByYear W21563062882018 @default.
• W2156306288 countsByYear W21563062882019 @default.
• W2156306288 countsByYear W21563062882020 @default.
• W2156306288 countsByYear W21563062882021 @default.
• W2156306288 countsByYear W21563062882022 @default.
• W2156306288 countsByYear W21563062882023 @default.
• W2156306288 crossrefType "journal-article" @default.
• W2156306288 hasAuthorship W2156306288A5001247907 @default.
• W2156306288 hasAuthorship W2156306288A5002644565 @default.
• W2156306288 hasAuthorship W2156306288A5005673493 @default.
• W2156306288 hasAuthorship W2156306288A5006277322 @default.
• W2156306288 hasAuthorship W2156306288A5014376121 @default.
• W2156306288 hasAuthorship W2156306288A5018464286 @default.

• next